Brian K. Link, MD | Authors

Diffuse Large B-Cell Lymphoma in the Elderly: Leaving Our Old Way(s) Behind?

February 16, 2013

Patients should ideally undergo very thoughtful evaluation with tools such as the comprehensive geriatric assessment or something similar that will give the treating physician the best estimate of therapy tolerance. Once therapy is initiated, very frequent monitoring is useful for providing early support of toxicity and for most promptly and effectively informing appropriate dose adjustments to ensure optimal dosing.

Identifying Appropriate Patient Groups and Drug Targets in DLBCL

May 15, 2012

In their article in this issue of ONCOLOGY, Nastoupil, Rose, and Flowers give a very careful assessment of the options for treating diffuse large B-cell lymphoma (DLBCL), with a focus on the importance of dose density in improving outcomes in this disease.